Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicriviroc in HIV-infected subjects
NCT00243568Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Sep 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of vicriviroc in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (3 arms), sponsored by Merck & Co. Primary endpoint: Virologic Response at 24 weeks. Planned start Sep 2005; status: withdrawn.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on NCT00243568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00243568.